Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy. In November 2018, the FDA granted accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results